医脉通 2025年业绩稳健增长，AI赋能持续推动平台能力提升

Investment Rating - The report maintains an "Outperform" rating for Medlive Technology [2][7] Core Insights - The company achieved a revenue of RMB 642 million in FY2025, representing a growth of 15.0%, primarily driven by the precision marketing segment [3][14] - The gross margin for FY2025 was 60.0%, an increase of 1.4 percentage points, indicating improved operational profitability [4][16] - The company is leveraging AI capabilities to enhance its product offerings, with a notable increase in monthly active users (MAU) to over 3.02 million, reflecting a growth of 14.0% [5][17] Financial Performance Summary - Revenue for FY2025 was RMB 642 million, with a breakdown as follows: - Precision marketing and enterprise solutions: RMB 595 million (+16.0%) - Medical knowledge solutions: RMB 19 million (+6.0%) - Intelligent patient management solutions: RMB 28.7 million (+2.4%) [3][14] - The adjusted net profit for FY2025 was RMB 342 million, a growth of 5.7%, with an adjusted net profit margin of 53.3% [4][16] - The company expects revenue for FY2026 and FY2027 to reach RMB 733 million and RMB 825 million, respectively, with year-on-year growth rates of 14.2% and 12.6% [7][18] Product and Market Development - The company launched an "AI + Medicine" product matrix, which includes MedSeeker, MedPaper, and MedAssister, enhancing its service offerings to pharmaceutical companies [5][17] - The management anticipates a 20% increase in marketed products in 2026, which is expected to support revenue growth [7][18]